Klinge Pharma 
Welcome,         Profile    Billing    Logout  
  Products    Diseases   Products    Trials    News 
2 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Ahzantive (aflibercept-mrbb) / Amneal, Formycon, Coherus Oncology, Klinge Pharma, Teva, MS Pharma, Alvogen, Valorum Biologics
FYB203-04-01, NCT06708637: Ocular Safety and Usability Study for FYB203 PFS

Completed
4
30
US
FYB203 2 mg (0.05 mL of 40 mg/mL), aflibercept-mrbb
Formycon AG
Age-Related Macular Degeneration, Branch Retinal Vein Occlusion with Macular Edema, Central Retinal Vein Occlusion with Macular Edema, Diabetic Macular Edema, Diabetic Retinopathy
10/24
10/24
MAGELLAN-AMD, NCT04522167 / 2019-003923-39: Efficacy and Safety of the Aflibercept FYB203 Biosimilar in Comparison to Eylea® in Patients With Neovascular Age-Related Macular Degeneration

Completed
3
434
Europe, Japan, RoW
FYB203 (Proposed aflibercept biosimilar), Eylea® (Aflibercept)
Bioeq GmbH
Neovascular Age-related Macular Degeneration
06/22
05/23
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Ahzantive (aflibercept-mrbb) / Amneal, Formycon, Coherus Oncology, Klinge Pharma, Teva, MS Pharma, Alvogen, Valorum Biologics
FYB203-04-01, NCT06708637: Ocular Safety and Usability Study for FYB203 PFS

Completed
4
30
US
FYB203 2 mg (0.05 mL of 40 mg/mL), aflibercept-mrbb
Formycon AG
Age-Related Macular Degeneration, Branch Retinal Vein Occlusion with Macular Edema, Central Retinal Vein Occlusion with Macular Edema, Diabetic Macular Edema, Diabetic Retinopathy
10/24
10/24
MAGELLAN-AMD, NCT04522167 / 2019-003923-39: Efficacy and Safety of the Aflibercept FYB203 Biosimilar in Comparison to Eylea® in Patients With Neovascular Age-Related Macular Degeneration

Completed
3
434
Europe, Japan, RoW
FYB203 (Proposed aflibercept biosimilar), Eylea® (Aflibercept)
Bioeq GmbH
Neovascular Age-related Macular Degeneration
06/22
05/23

Download Options